GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Placing to raise £1.25 million

25 Jan 2011 07:00

RNS Number : 9952Z
ViaLogy PLC
25 January 2011
 



 

ViaLogy PLC ("ViaLogy" or "the Company")

Placing to raise £1.25 million

London, January 25, 2011. ViaLogy (LSE:VIY) is pleased to announce that it has today raised £1.25 million through the placing of 41,666,664 new ordinary shares of 1p each ("Placing Shares") at a price of 3p per share with certain existing shareholders ("the Placing").

The net proceeds of the Placing will be used in the further expansion of ViaLogy's energy business which uses its proprietary QuantumRD™ technology to discover and characterise hydrocarbon reservoirs and generate drilling targets.

Application has been made for the 41,666,664 Placing Shares to be admitted to trading on AIM and dealings are expected to commence on 31 January 2011. Following the Placing, the total number of ordinary shares in issue and therefore the total number of voting rights is 733,941,998.

Terry Bond, chairman of ViaLogy commented: "This funding will help to provide a firm financial base during what promises to be a very important year for the company. At the beginning of 2010, and with our previous series of successful wells in Texas as a launching pad, the board took a deliberate decision to focus our attention on global E&P companies as the path to establish QuantumRD, a novel realisation of seismic interferometry, as a standard industry platform. This, we believe, is where the commercial future of our company lies.

"The new funds will permit some expansion of our capacity to meet anticipated contract demand for new offshore prospects in the near term. As previously announced, we have made significant progress in the past twelve months in gaining the acceptance of a new technology in the upstream E&P sector. We concluded a Master Services contract with a supermajor and are working on our first project for them; in addition, following successful completion of a technology demonstration project, we are in advanced talks with a Fortune Global 100 international E&P firm. Other talks are underway with a non-US national oil company. The discussions focus on large core projects, both onshore and offshore, which we expect will lead to commercial contracts. We have also received enquiries from some of the large international oilfield services firms, and we are in advanced discussions with one of them in relation to a possible strategic partnership." 

Options Grant

Under the terms of his employment contract entered into on June 22nd, 2010, Dr. Sandeep Gulati, ViaLogy's founder and Chief Technology Officer, is entitled to additional options awards in order to retain his interest in the ordinary share capital of ViaLogy. The Company has therefore issued 3,967,360 options exercisable at 1p per share. 

For further information please contact:

 

ViaLogy PLC 

 

 

 

 

 

Terry Bond, Chairman - UK & Europe

 

+44 (0) 1235 834734

 

 

 

 

 

 

Seymour Pierce Limited

Nominated Advisor and Broker to ViaLogy

 

 

 

 

 

Mark Percy / Catherine Leftley

(Corporate Finance)

Katie Ratner/Jeremy Stephenson

(Corporate Broking)

 

+44 (0) 207 107 8000

Except for statements of historical fact, the information presented herein constitutes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOEUSSNRASAAUAR
Date   Source Headline
14th Dec 20217:00 amRNSHalf-year Report
6th Dec 20217:00 amRNSNotice of Half-year results
18th Nov 20217:00 amRNSDPYD screening recommended in Spain
28th Oct 20217:00 amRNSRanger® Technology to be presented at Labroots
26th Oct 20217:00 amRNSHalf-year Trading update
29th Sep 20217:00 amRNSResult of AGM
28th Sep 20213:00 pmRNSAGM update
28th Sep 20217:00 amRNSAGM Statement
15th Sep 20217:00 amRNSShare option awards
1st Sep 20217:00 amRNSISO 15189:2012 accreditation received
1st Sep 20217:00 amRNSNotice of AGM and Annual Report 2021
19th Aug 202112:04 pmRNSCOVID-19 Surge testing contract
11th Aug 20217:01 amRNSEarn-out Milestone, Issue of Equity & TVR
11th Aug 20217:00 amRNSAudited Final results&unaudited Q1 business update
6th Aug 20217:00 amRNSConfirmation of Results Date
23rd Jul 20217:00 amRNSNotice of Results
1st Jul 202111:09 amRNSHolding(s) in Company
21st Jun 20217:00 amRNSSecond Strategic Partner for Coastal Genomics
18th Jun 20217:00 amRNSContract Award: DPYD testing kits for NHS Wales
17th Jun 20214:32 pmRNSExercise of Options
9th Jun 20217:00 amRNSMulti-year licence and supply agreement
21st May 20214:30 pmRNSDirector/PDMR Shareholding
19th May 20217:00 amRNSDistribution Partnership
18th May 20217:00 amRNSLaunch of IONA Care NIPT service offering
17th May 20217:00 amRNSFurther testing service agreement for MHC
29th Apr 20217:00 amRNSFull year Trading update
26th Apr 20217:00 amRNSFurther National Microbiology Framework awards
19th Apr 20211:21 pmRNSFurther National Microbiology Framework contract
19th Apr 20217:00 amRNSNational Framework contract award
12th Apr 20217:00 amRNSEarn-out Milestone, Issue of Equity & TVR
6th Apr 20212:43 pmRNSTesting service agreement with MyHealthCheckedplc
6th Apr 20211:54 pmRNSAgreement with Boots for COVID-19 sample kits
29th Mar 20214:00 pmRNSCOVID-19 update
23rd Mar 20217:00 amRNSShare option exercises and awards
19th Mar 20217:00 amRNSTwin Pregnancy study published using IONA® Test
17th Mar 20217:00 amRNSAppointment of VP of Sales North America
11th Mar 20217:00 amRNSYourgene Genomic Services portfolio expansion
1st Mar 20217:00 amRNSFirst US Supply Agreement
22nd Feb 20217:00 amRNSPartnership with NPH
10th Feb 202110:51 amRNSCorrection: Director / PDMR Shareholding
10th Feb 20217:00 amRNSDirector/PDMR Shareholding
8th Feb 20217:00 amRNSTrading update
13th Jan 20217:00 amRNSDPYD screening recommended in Belgium
11th Jan 20217:00 amRNSClarigene® SARS-CoV-2 Product Update
8th Jan 20217:00 amRNSIssue of Share Options
24th Dec 20207:00 amRNSCOVID-19 update
17th Dec 20207:00 amRNSHalf-year Report
15th Dec 20207:00 amRNSNotice of Half-year Results
2nd Dec 20207:00 amRNSDPYD kits recommended by NHS England
2nd Dec 20207:00 amRNSGenomic testing service launch and Change of name

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.